Search by Drug Name or NDC
NDC 51672-4194-07 Clindamycin Phosphate 10 mg/g Details
Clindamycin Phosphate 10 mg/g
Clindamycin Phosphate is a TOPICAL AEROSOL, FOAM in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Taro Pharmaceuticals U.S.A., Inc.. The primary component is CLINDAMYCIN PHOSPHATE.
MedlinePlus Drug Summary
Topical clindamycin is used to treat acne. Clindamycin is in a class of medications called lincomycin antibiotics. It works by slowing or stopping the growth of bacteria that cause acne and by decreasing swelling.
Related Packages: 51672-4194-07Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Clindamycin Topical
Product Information
| NDC | 51672-4194 |
|---|---|
| Product ID | 51672-4194_357bd300-1ff2-4c79-8310-21c1da2fd8d8 |
| Associated GPIs | |
| GCN Sequence Number | 058418 |
| GCN Sequence Number Description | clindamycin phosphate FOAM 1 % TOPICAL |
| HIC3 | Q5W |
| HIC3 Description | TOPICAL ANTIBIOTICS |
| GCN | 23848 |
| HICL Sequence Number | 004045 |
| HICL Sequence Number Description | CLINDAMYCIN PHOSPHATE |
| Brand/Generic | Generic |
| Proprietary Name | Clindamycin Phosphate |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Clindamycin Phosphate |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | AEROSOL, FOAM |
| Route | TOPICAL |
| Active Ingredient Strength | 10 |
| Active Ingredient Units | mg/g |
| Substance Name | CLINDAMYCIN PHOSPHATE |
| Labeler Name | Taro Pharmaceuticals U.S.A., Inc. |
| Pharmaceutical Class | Decreased Sebaceous Gland Activity [PE], Lincosamide Antibacterial [EPC], Lincosamides [CS], Neuromuscular Blockade [PE] |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA210004 |
| Listing Certified Through | 2024-12-31 |
Package
Package Images
NDC 51672-4194-07 (51672419407)
| NDC Package Code | 51672-4194-7 |
|---|---|
| Billing NDC | 51672419407 |
| Package | 1 CAN in 1 CARTON (51672-4194-7) / 100 g in 1 CAN |
| Marketing Start Date | 2022-10-01 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |
Standard Product Labeling (SPL)/Prescribing Information SPL 9dd8b4f9-9db8-4a16-abcd-bf32219e0301 Details
HIGHLIGHTS OF PRESCRIBING INFORMATION
CLINDAMYCIN PHOSPHATE foam, 1%
For Topical Use
Initial U.S. Approval: 1970
INDICATIONS AND USAGE
Clindamycin phosphate foam is a lincosamide product indicated for acne vulgaris in patients 12 years and older. (1)
DOSAGE AND ADMINISTRATION
DOSAGE FORMS AND STRENGTHS
Foam containing 1% clindamycin as clindamycin phosphate. (3)
CONTRAINDICATIONS
Clindamycin phosphate foam is contraindicated in individuals with a history of regional enteritis or ulcerative colitis, or a history of antibiotic-associated colitis, (including pseudomembranous colitis). (4)
WARNINGS AND PRECAUTIONS
Colitis: Clindamycin can cause severe colitis, which may result in death. Diarrhea, bloody diarrhea, and colitis (including pseudomembranous colitis) have been reported with the use of clindamycin. Clindamycin phosphate foam should be discontinued if significant diarrhea occurs. (5.1)
ADVERSE REACTIONS
The most common adverse reactions (>1%) are headache and application site reactions including burning, pruritus, and dryness. (6.1)
To report SUSPECTED ADVERSE REACTIONS, contact Taro Pharmaceuticals U.S.A., Inc. at 1-866-923-4914 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.
Revised: 1/2021
Table Of Contents
FULL PRESCRIBING INFORMATION: CONTENTS*
1 INDICATIONS AND USAGE
2 DOSAGE AND ADMINISTRATION
3 DOSAGE FORMS AND STRENGTHS
4 CONTRAINDICATIONS
5 WARNINGS AND PRECAUTIONS
5.1 Colitis
5.2 Irritation
6 ADVERSE REACTIONS
6.1 Clinical Trials Experience
6.2 Postmarketing Experience
7 DRUG INTERACTIONS
7.1 Erythromycin
7.2 Neuromuscular Blocking Agents
8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
8.2 Lactation
8.4 Pediatric Use
8.5 Geriatric Use
11 DESCRIPTION
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
12.2 Pharmacodynamics
12.3 Pharmacokinetics
12.4 Microbiology
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
14 CLINICAL STUDIES
16 HOW SUPPLIED/STORAGE AND HANDLING
16.1 How Supplied
16.2 Storage and Handling
17 PATIENT COUNSELING INFORMATION
17.1 Instructions for Use
17.2 Skin Irritation
17.3 Colitis
- *
- Sections or subsections omitted from the full prescribing information are not listed.
1 INDICATIONS AND USAGE
2 DOSAGE AND ADMINISTRATION
Clindamycin phosphate foam is for topical use only, and not for oral, ophthalmic, or intravaginal use.
Apply clindamycin phosphate foam once daily to affected areas after the skin is washed with mild soap and allowed to fully dry. Use enough to cover the entire affected area.
If there has been no improvement after 6 to 8 weeks or if the condition becomes worse, treatment should be discontinued.
The contents of clindamycin phosphate foam are flammable; avoid fire, flame and/or smoking during and immediately following application.
3 DOSAGE FORMS AND STRENGTHS
4 CONTRAINDICATIONS
5 WARNINGS AND PRECAUTIONS
5.1 Colitis
Systemic absorption of clindamycin has been demonstrated following topical use of this product. Diarrhea, bloody diarrhea, and colitis (including pseudomembranous colitis) have been reported with the use of topical clindamycin. If significant diarrhea occurs, clindamycin phosphate foam should be discontinued [see Adverse Reactions (6.2)].
Severe colitis has occurred following oral or parenteral administration of clindamycin with an onset of up to several weeks following cessation of therapy. Antiperistaltic agents such as opiates and diphenoxylate with atropine may prolong and/or worsen severe colitis. Severe colitis may result in death.
Studies indicate a toxin(s) produced by Clostridia is one primary cause of antibiotic-associated colitis. The colitis is usually characterized by severe persistent diarrhea and severe abdominal cramps and may be associated with the passage of blood and mucus. Stool cultures for Clostridium difficile and stool assay for C. difficile toxin may be helpful diagnostically.
5.2 Irritation
Clindamycin phosphate foam can cause irritation. Concomitant topical acne therapy should be used with caution since a possible cumulative irritancy effect may occur, especially with the use of peeling, desquamating, or abrasive agents. If irritation or dermatitis occurs, clindamycin should be discontinued.
Avoid contact of clindamycin phosphate foam with eyes, mouth, lips, other mucous membranes or areas of broken skin. If contact occurs, rinse thoroughly with water.
Clindamycin phosphate foam should be prescribed with caution in atopic individuals.
6 ADVERSE REACTIONS
6.1 Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
A total of 439 subjects with mild to moderate acne vulgaris were treated once daily for 12 weeks with clindamycin phosphate foam.
The incidence of adverse reactions occurring in ≥1% of the subjects in clinical trials comparing clindamycin phosphate foam and its vehicle is presented in Table 1.
| Adverse Reactions | Number (%) of Subjects | |
|---|---|---|
| Clindamycin Phosphate Foam N = 439 | Vehicle Foam N = 154 |
|
| Headache | 12 (3%) | 1 (1%) |
| Application site burning | 27 (6%) | 14 (9%) |
| Application site pruritus | 5 (1%) | 5 (3%) |
| Application site dryness | 4 (1%) | 5 (3%) |
| Application site reaction, not otherwise specified | 3 (1%) | 4 (3%) |
In a contact sensitization study, none of the 203 subjects developed evidence of allergic contact sensitization to clindamycin phosphate foam.
6.2 Postmarketing Experience
The following adverse reactions have been identified during post approval use of clindamycin phosphate foam: application site pain, application site erythema, diarrhea, urticaria, abdominal pain, hypersensitivity, rash, abdominal discomfort, nausea, seborrhea, application site rash, dizziness, pain of skin, colitis (including pseudomembranous colitis), and hemorrhagic diarrhea. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Abdominal pain and gastrointestinal disturbances, as well as gram-negative folliculitis, have also been reported in association with the use of topical formulations of clindamycin. Orally and parenterally administered clindamycin have been associated with severe colitis, which may end fatally.
7 DRUG INTERACTIONS
7.1 Erythromycin
Clindamycin phosphate foam should not be used in combination with topical or oral erythromycin-containing products due to possible antagonism to its clindamycin component. In vitro studies have shown antagonism between these two antimicrobials. The clinical significance of this in vitro antagonism is not known.
8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
Risk Summary
There are no available data on clindamycin phosphate foam use in pregnant women to inform a drug-associated risk for adverse developmental outcomes.
Animal reproduction studies have not been conducted with clindamycin phosphate foam. No evidence of fetal harm or malformations was observed in pregnant rats and mice administered daily subcutaneous or oral doses of clindamycin salts during organogenesis at doses that produced exposures up to 84 and 42 times, respectively, the maximum recommended human dose (MRHD) of clindamycin phosphate foam based on body surface area (BSA) comparisons and assuming 100% absorption [see Data].
In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
Data
Animal Data
Reproduction studies have been conducted in rats and mice using subcutaneous or oral doses of clindamycin phosphate, clindamycin hydrochloride or clindamycin palmitate hydrochloride administered daily during organogenesis at doses up to the equivalent of 432 mg/kg/day clindamycin phosphate. These studies produced no evidence of fetal harm or malformations in rats or mice at exposures 84 or 42 times, respectively, the MRHD of clindamycin phosphate (i.e., 5 milliliters of clindamycin phosphate foam) based on BSA comparison and assuming 100% absorption.
8.2 Lactation
Risk Summary
There is no information on the presence of clindamycin in human milk, or the effects on the breast-fed child, or the effects on milk production following use of clindamycin phosphate foam. However, orally and parenterally administered clindamycin has been reported to appear in breast milk.
The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for clindamycin phosphate foam and any potential adverse effects on the breast-fed child from clindamycin phosphate foam or from the underlying maternal condition.
11 DESCRIPTION
Clindamycin phosphate foam contains clindamycin (1%) as clindamycin phosphate. Clindamycin phosphate is a water-soluble ester of the semi-synthetic antibiotic produced by a 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the parent antibiotic, lincomycin.
The chemical name for clindamycin phosphate is methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-threo-α-D-galacto-octopyranoside 2-(dihydrogen phosphate). The structural formula for clindamycin phosphate is represented below:
Molecular Formula: C18H34ClN2O8PS
Molecular Weight: 504.97 g/mol
Clindamycin phosphate foam contains clindamycin (1%) as clindamycin phosphate, USP at a concentration equivalent to 10 mg clindamycin per gram in a thermolabile hydroethanolic foam vehicle consisting of cetyl alcohol, dehydrated alcohol, polysorbate 60, propylene glycol, purified water, and stearyl alcohol pressurized with a hydrocarbon (propane/butane) propellant.
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
Mechanism of action of clindamycin in acne vulgaris is unknown [see Microbiology (12.4)].
12.3 Pharmacokinetics
In an open label, parallel group study in 24 subjects with acne vulgaris, 12 subjects (3 male and 9 female) applied 4 grams of clindamycin phosphate foam once-daily for five days, and 12 subjects (7 male and 5 female) applied 4 grams of a clindamycin gel, 1%, once daily for five days. On Day 5, the mean Cmax and AUC(0-12) were 23% and 9% lower, respectively, for clindamycin phosphate foam than for the clindamycin gel, 1%.
Following multiple applications of clindamycin phosphate foam, less than 0.024% of the total dose was excreted unchanged in the urine over 12 hours on Day 5.
12.4 Microbiology
No microbiology studies were conducted in the clinical trials with this product.
Clindamycin binds to the 50S ribosomal subunits of susceptible bacteria and prevents elongation of peptide chains by interfering with peptidyl transfer, thereby suppressing protein synthesis. Clindamycin has been shown to have in vitro activity against Propionibacterium acnes (P. acnes), an organism that has been associated with acne vulgaris; however, the clinical significance of this activity against P. acnes was not examined in clinical studies with clindamycin phosphate foam. P. acnes resistance to clindamycin has been documented.
Inducible Clindamycin Resistance
The treatment of acne with antimicrobials is associated with the development of antimicrobial resistance in P. acnes as well as other bacteria (e.g. Staphylococcus aureus, Streptococcus pyogenes). The use of clindamycin may result in developing inducible resistance in these organisms. This resistance is not detected by routine susceptibility testing.
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
The carcinogenicity of a 1.2% clindamycin phosphate gel similar to clindamycin phosphate foam was evaluated by daily topical administration to mice for two years. The topical doses used in this study were approximately 3 and 15 times higher than the MRHD of clindamycin phosphate from clindamycin phosphate foam, based on BSA comparison and assuming 100% absorption. No significant increase in tumors was noted in the treated animals.
The genotoxic potential of clindamycin was evaluated in an in vitro Ames assay and in an in vivo rat micronucleus test. Both tests were negative.
Reproduction studies in rats using oral doses of clindamycin hydrochloride or clindamycin palmitate hydrochloride have revealed no evidence of impaired fertility.
14 CLINICAL STUDIES
In one multicenter, randomized, double-blind, vehicle-controlled clinical trial, subjects with mild to moderate acne vulgaris used clindamycin phosphate foam or the vehicle foam once daily for twelve weeks. Treatment response, defined as the proportion of subjects clear or almost clear, based on the Investigator Static Global Assessment (ISGA), and the mean percent reductions in lesion counts at the end of treatment in this study are shown in Table 2.
16 HOW SUPPLIED/STORAGE AND HANDLING
16.1 How Supplied
Clindamycin phosphate foam, 1% contains 10 mg of clindamycin as clindamycin phosphate, USP per gram. The white to off-white thermolabile foam is available as follows:
- 100 gram aerosol can - NDC 51672-4194-7
- 50 gram aerosol can - NDC 51672-4194-3
16.2 Storage and Handling
Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].
Flammable. Avoid fire, flame or smoking during and immediately following application.
Contents under pressure. Do not puncture or incinerate. Do not expose to heat or store at temperature above 120°F (49°C). Keep out of reach of children.
17 PATIENT COUNSELING INFORMATION
See FDA-Approved patient labeling (Patient Information).
17.1 Instructions for Use
- Patients should be advised to wash their skin with mild soap and allow it to dry before applying clindamycin phosphate foam.
- Patients should use enough clindamycin phosphate foam to cover the face and to apply once daily.
- Patients should dispense clindamycin phosphate foam directly into the cap or onto a cool surface.
- Patients should wash their hands after applying clindamycin phosphate foam.
SPL UNCLASSIFIED SECTION
SPL UNCLASSIFIED SECTION
| PATIENT INFORMATION Clindamycin Phosphate (klin'' da mye' sin fos' fate) Foam, 1% |
|
|---|---|
| This Patient Information has been approved by the U.S. Food and Drug Administration. | Revised: 1/2021 |
| Important Information: Clindamycin phosphate foam is for use on the skin only. Do not use clindamycin phosphate foam in your eyes, mouth or vagina. | |
| What is Clindamycin Phosphate Foam?
Clindamycin phosphate foam is a prescription medicine used on the skin (topical) to treat acne vulgaris in people 12 years and older. It is not known if clindamycin phosphate foam is safe and effective in children under 12 years of age. |
|
| Who should not use Clindamycin Phosphate Foam? Do not use clindamycin phosphate foam if you:
|
|
| What should I tell my doctor before using Clindamycin Phosphate Foam? Before using clindamycin phosphate foam, tell your doctor about all of your medical conditions, including if you:
Clindamycin phosphate foam may affect the way other medicines work and other medicines may affect how clindamycin phosphate foam works. Especially tell your doctor if you take medicine by mouth that contains erythromycin or use products on your skin that contain erythromycin. Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine. |
|
How should I use Clindamycin Phosphate Foam?
|
|
What should I avoid while using Clindamycin Phosphate Foam?
|
|
| What are possible side effects with Clindamycin Phosphate Foam?
Clindamycin phosphate foam may cause serious side effects, including:
|
|
| The most common side effects of clindamycin phosphate foam include headache and application site reactions (including burning, itching, and dryness). These are not all the possible side effects of clindamycin phosphate foam. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. |
|
How should I store Clindamycin Phosphate Foam?
|
|
| Keep clindamycin phosphate foam and all medicines out of the reach of children. | |
| General information about the safe and effective use of Clindamycin Phosphate Foam.
Medicines are sometimes prescribed for purposes other than those listed in Patient Information leaflet. Do not use clindamycin phosphate foam for a condition for which it was not prescribed. Do not give clindamycin phosphate foam to other people, even if they have the same symptoms you have. It may harm them. You can also ask your pharmacist or doctor for information about clindamycin phosphate foam that is written for health professionals. |
|
| What are the ingredients in Clindamycin Phosphate Foam?
Active ingredient: clindamycin phosphate Inactive ingredients: cetyl alcohol, dehydrated alcohol, polysorbate 60, propylene glycol, purified water, and stearyl alcohol. The can is pressurized with a hydrocarbon (propane/butane) propellant. |
|
INSTRUCTIONS FOR USE
| Instructions for Use Clindamycin Phosphate (klin'' da mye' sin fos' fate) Foam, 1% |
|
|---|---|
| Important Information: Clindamycin phosphate foam is for use on the skin only. Do not use clindamycin phosphate foam in your eyes, mouth or vagina. | |
| Step 1: Remove the clear cap from the clindamycin phosphate foam can. |  |
Step 2: Hold the can upright and firmly press the nozzle to dispense clindamycin phosphate foam into the clear cap.
|  |
|  |
| Step 3: Pick up small amounts of clindamycin phosphate foam with your fingertips and gently rub the foam into the affected area until the foam disappears. |  |
Step 4: Wash your hands after applying clindamycin phosphate foam.
|
|
How should I store Clindamycin Phosphate Foam?
- Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].
- Keep clindamycin phosphate foam away from heat. Never throw the can into a fire, even if the can is empty.
- Do not store clindamycin phosphate foam at temperatures above 120°F (49°C).
- Do not break through (puncture) the clindamycin phosphate foam can.
Keep clindamycin phosphate foam and all medicines out of the reach of children.
The Patient Information and Instructions for Use have been approved by the U.S. Food and Drug Administration.
Mfd. by: Taro Pharmaceutical Industries Ltd.
Haifa Bay, Israel 2624761
Dist. by: Taro Pharmaceuticals U.S.A., Inc.
Hawthorne, NY 10532
Issued: January 2021
5201411-0121-0
80
PRINCIPAL DISPLAY PANEL - 50 g Can Carton
INGREDIENTS AND APPEARANCE
| CLINDAMYCIN PHOSPHATE
clindamycin phosphate aerosol, foam |
||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
| Labeler - Taro Pharmaceuticals U.S.A., Inc. (145186370) |
| Establishment | |||
| Name | Address | ID/FEI | Business Operations |
|---|---|---|---|
| Taro Pharmaceutical Industries, Ltd. | 600072078 | MANUFACTURE(51672-4194) | |